Tag Archive for: Abrysvo

The company said in a press release that the vaccine’s efficacy against RSV-associated lower respiratory tract disease with three or more symptoms was 77.8% through season two, compared with efficacy of 88.9% after the first RSV season, which led to the shot’s U.S. approval.

The U.S. Food and Drug Administration on Monday approved Pfizer’s (PFE.N) respiratory syncytial virus (RSV) vaccine for use in women during the middle of the third trimester of pregnancy to protect their babies.

British biopharmaceutical giant GSK sued Pfizer in Delaware federal court on Wednesday, accusing Pfizer’s respiratory syncytial virus (RSV) vaccine Abrysvo of violating GSK’s patent rights in its rival RSV shot Arexvy.

A panel of advisers to the U.S. Centers for Disease Control and Prevention (CDC) on Wednesday recommended that new vaccines from Pfizer and GSK to prevent severe respiratory syncytial virus (RSV) infections be available to older adults in the U.S. but stopped short of saying all of them should get the shots.

A panel of advisers to the U.S. Centers for Disease Control and Prevention (CDC) on Wednesday will vote on whether to recommend the use of recently approved vaccines from Pfizer and GSK to prevent severe respiratory syncytial virus (RSV) infections in older adults.

The FDA has approved Pfizer’s respiratory syncytial virus vaccine, henceforth to carry the brand name Abrysvo, to prevent lower respiratory tract disease in older adults aged 60 years and above, the company announced Wednesday.

Abrysvo, Pfizer’s investigational vaccine for respiratory syncytial virus infection, appears to be safe and effective in the pediatric setting, according to the FDA’s briefing document published ahead of an advisory committee meeting.